The study was conducted as a phase IV, double-blind, multicentre, active-controlled clinical trial. The institutional review board of each participating study site approved the protocol prior to ...

After more than three decades working as a constable for the District Court of Maryland, 78-year-old Thomas O’Rourke is one ...

When patients can’t access their MHT patches, they may consider switching to different formulations, such as tablets or gels.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA. Health Canada has previously granted approval to initiate this Phase 2 ...

The clinical practice update offers 12 “best practice advice” statements on POEM to treat achalasia and other esophageal ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025Management ViewCEO Dave Rosa highlighted the strong performance ...